Mesa Laboratories plans restructuring with $2.6 million to $3.4 million in pre-tax charges
Mesa Laboratories approved a restructuring program that eliminates about 40 positions, mainly in its Clinical Genomics division, and exits its Hamburg, Germany facility when its lease expires in February 2027. The company expects a net annualized cost reduction of about $5.0 million after reinvestment, but says Clinical Genomics revenue will be lower as it narrows its focus to pharmacogenomics and oncology.
Key points
- Estimated total pre-tax charges of $2.6 million to $3.4 million, mainly in the second half of fiscal year 2027
- Expected related cash expenditures of $2.9 million to $3.7 million, substantially all over the next 12 months
- Savings plan to reduce annualized operating costs by about $9.3 million, with about $4.3 million reinvested
- Company will report second quarter fiscal year 2027 results and provide fiscal 2027 guidance on November 9, 2026
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.